Back to results
US 2013/0281402 A1Published application
Hdac inhibiting derivatives of camptothecin
AssigneeCrystal Biopharmaceutical LLC
InventorsYi Chen, Yu Chen
Life of this patent
Estimating the term…
Abstract
The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.
Claims15
A compound of Formula I, or a pharmaceutically acceptable salt thereof:
- wherein
- Z is deleted, C(RaRb), (CH2)p, (CH2)pNH(CH2)q, CH═N, O, S, C(O), N(Ra), SO2, OC(O), C(O)O, OSO2, S(O2)O, C(O)S, SC(O), C(O)C(O), C(O)N(Ra), N(Ra)C(O), S(O2)N(Ra), N(Ra)S(O2), OC(O)O, OC(O)S, OC(O)N(Ra), OC(O)NH(CH2)p+1NH(CH2)q, N(Ra)C(O)O, N(Ra)C(O)S, or N(Ra)C(O)N(Rb), in which each of Ra and Rb, independently, is H, alkyl, alkenyl, or alkynyl;
- each of p and q, independently, is 0, 1, 2, 3, or 4;
- each R1, R2, and R3, independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, —CH═NH, oxo, cyano, Si(RcRcRc), alkyl-Si(RcRcRc), alkyl-Rc, alkyl-NRcRc, —CH═NORc, ORc, OC(O)Rc, OC(O)ORc, OC(O)SRc, SRc, C(O)Rc, C(O)ORc, C(O)SRc, C(O)NRcRc, SORc, SO2Rc, NRcRc, N(Rc)C(O)Rc, in which each of Rc independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, cyano, nitro, amino, hydroxyl, alkylamino, haloalkyl, or alkoxy, or R1, R2, and the atoms to which they are attached are taken together form a ring, which is optionally substituted with Rc;
- L is —(CH2)m—,
- in which m is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;
- each of n and o, independently, is 1, 2, 3, or 4;
- and each W1 and W2, independently, is CH or N.
5 more elements
An anti-cancer agent simultaneously containing a hydroxamic acid pharmacophore capable of inhibiting histone deacetylases (HDAC) and a pharmacophore capable of inhibiting topoisomerases.
Dependencies are inferred from the claim text.